Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Available until 12/1/2023

Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.

Already Have An Account? Log in Now

Published in Dermatology

Journal Scan / Research · October 04, 2023

Risk of Malignancies in Patients With Psoriasis Treated With IL-17 and IL-23 Inhibitors

Journal of the European Academy of Dermatology and Venereology: JEADV




This abstract is available on the publisher's site.

Access this abstract now  

Additional Info

Journal of the European Academy of Dermatology and Venereology: JEADV
Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? - Insights from an international population-based study
J Eur Acad Dermatol Venereol 2023 Sep 20;[EPub Ahead of Print], K Kridin, M Abdelghaffar, N Mruwat, RJ Ludwig, D Thaçi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading